Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.

about

Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine.

Item

http://www.wikidata.org/entity/Q38694505

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Acquired temozolomide resistan ...... can be overcome by lomustine.

@en

type

Item

label

Acquired temozolomide resistan ...... can be overcome by lomustine.

@en

prefLabel

Acquired temozolomide resistan ...... can be overcome by lomustine.

@en

P1476

Acquired temozolomide resistan ...... d can be overcome by lomustine

@en

P2093

J Stritzelberger

http://www.w3.org/2001/XMLSchema#string

L Distel

http://www.w3.org/2001/XMLSchema#string

R Buslei

http://www.w3.org/2001/XMLSchema#string

R Fietkau

http://www.w3.org/2001/XMLSchema#string

P2860

Nonsurgical treatment of recurrent glioblastoma

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry.

Analysis of apoptosis by laser scanning cytometry.

Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.

Targeting DNA mismatch repair for radiosensitization.

P2888

s12094-017-1743-x

P304

508-516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12094-017-1743-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Florian Putz

P577

2017-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28825189

http://www.w3.org/2001/XMLSchema#string